Salmonics a biotechnology company specializing in fish blood-based biomedical products, has announced a strategic investment from Norwegian salmon farming giant, the Lerøy Seafood Group.
Salmonics develops and markets reagents and biomedical products from the blood of salmon and other fish species. Their products support applications in regenerative medicine, cell proliferation, clotting, wound care, and pain treatment.
The terms of the investment have not been disclosed.
Lerøy, based in Norway, reported revenues exceeding NOK 30 billion ($2.8 billion) in 2023.
This investment into Brunswick, Maine-based Salmonics underscores Lerøy’s confidence in the innovative biotechnological solutions and patents developed by Salmonics, positioning both companies for expansion in the biotechnology and pharmaceutical sectors, according to a release from the company.
“This collaboration between Salmonics and Lerøy will usher in new opportunities to expand the use of our fish blood-based biomedical products globally,” said President and CEO of Salmonics Dr. Cem Giray.
“Lerøy’s expertise and commitment to sustainability align perfectly with our mission to transform aquaculture and fisheries byproducts into valuable resources for improving patient care and outcomes while potentially lowering healthcare costs.”
Henning Beltestad, CEO of Lerøy, commented, “We are excited to support the work Salmonics has undertaken to advance biotechnological solutions utilizing farmed fish, increasing value and meeting our sustainable development goals. This investment reflects our commitment to innovative solutions that enhance the efficiency and potential of the seafood value chain while delivering positive benefits to healthcare.”
Lerøy, headquartered in Bergen, Norway, is a global seafood leader with approximately 6,000 employees, operations in 15 countries, and sales in over 80 markets. The company handles up to 400,000 tons of seafood annually.
